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Background: Amyloidosis leads to deposition of abnormal protein with beta-pleated sheet structure in specific
compartments of the affected organs. The histological localization of these amyloid deposits determines the overall
survival of the patient.
Methods: In this study we have assessed the histological localization and severity of amyloid deposition in 35
patients with biopsy-proven renal amyloidosis and have compared those to clinical parameters, histo-pathological
injury criteria and respective patient outcome. Comparisons were statistically analyzed using thus comparison
between the different study groups, which was done using Student t-test and analysis of variance.
Results: We find that the glomerulus is by far the most commonly and most severely affected renal compartment
and patients with severe glomerular amyloidosis advance faster towards end stage renal disease (ESRD) and death,
compared to those patients without glomerular amyloid deposits. Patients with severe glomerular amyloidosis
showed higher serum creatinine and urine protein levels, while patients with severe vascular amyloidosis showed
higher levels of interstitial inflammatory infiltrate.
Conclusion: In kidneys affected by amyloidosis, the amyloid proteins are predominantly deposited along vessels,
especially the small vessels including glomerular capillary loops. The severity of glomerular amyloid deposition
enhances the risk of developing ESRD and increases the risk for premature death.
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Renal amyloidosis is caused by deposits of abnormally
folded protein with a beta pleated sheet structure in the
kidney [1]. These insoluble beta-strands form rope–like
amyloid fibrils, which are non-branching and 8-10 nm
thick. Such deposits of amyloid protein in vital organs,
including the kidney, heart, and muscle, lead to organ
dysfunction and are associated with significant morbidity
and mortality [2]. Impairment of renal function is a
common manifestation of systemic amyloidosis and is
often the main cause of morbidity and mortality. Distri-
bution of amyloid differs among patients in regard to
organ localization. Different types of amyloid can be* Correspondence: gilbert.moeckel@yale.edu
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unless otherwise stated.seen in renal amyloidosis, but most common are light
chain amyloid (AL), associated with multiple myeloma
or B cell lymphomas, and acute phase protein-associated
amyloid, serum amyloid A (SAA), which can be seen in
patients chronic infectious or inflammatory diseases [3].
The annual incidence of AL amyloidosis is estimated at
5-12 cases per million [4], and is the most common
form of amyloidosis in developed countries. The amount
of circulating light chains may be fairly small and only
about 15% of patients with AL amyloidosis fulfill the cri-
teria for multiple myeloma. Significant AA amyloid de-
position is dependent on duration of inflammation,
magnitude of SAA response and SAA1 homozygosity
[5]. AA amyloidosis commonly affects the kidneys and
often shows faster progression towards ESRD [2,6].
The correct diagnosis of renal amyloidosis is dependent
on the light microscopic findings of eosinophilic amorphousl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Amyloid Classification
Class 0: No amyloid deposition
Class 1: Minimal Mesangial (<10%)
Class 2: Mild Mesangial (10-25%)
Class 3: Focal mesangiocapillary (26-50%)
Class 4: Diffuse mesangiocapillary (51-75%)
Class 5: Membranous
Class 6: Advanced (>76%)
Class dependent on % of tuft and glomerular compartment involved.
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red positive and apple green birefringent upon polarization
[7]. Moreover, characteristic immunohistochemistry posi-
tivity for kappa or lambda light chains or SAA precursor
protein supports the diagnosis for AL or AA amyloidosis
respectively [8]. Confirmation of amyloid deposits with
non-branching, fibrillary substructure by electron micros-
copy is essential [9].
Depending on the respective organ affected by amyl-
oidosis, typical clinical symptoms of dysfunction and
insufficiency ensue. Impaired organ function due to
amyloidosis has been clinically divided into mild, moder-
ate and severe, and has been associated with progres-
sively worse outcome for the patient [10]. The extent
and distribution of amyloid deposits in the kidney and
the rate of accumulation of new amyloid deposits are
important prognostic indicators. The progression of
amyloidosis is dependent on the production and concen-
tration of circulating precursor protein, which correlates
with deterioration of kidney function [11]. Reduction of
SAA serum concentrations in patients with AA amyloid-
osis improved patient survival [2]. However, an outcome
study based on histological localization and amount of
amyloid deposits in specific compartments of the kidney
has not been performed to date.
In an attempt to standardize pathology reports for renal
amyloidosis similar to the lupus nephritis classification, a
classification system has been proposed that is based on
amyloid deposition in different compartments of the
glomerulus [12]. However, this study did not correlate the
biopsy classification with clinical outcome. The goal of
our study is to evaluate whether the presence of amyloid
deposits in a particular renal compartment (glomerular vs.
vascular vs. interstitial) may affect patient outcome, in-
cluding progression to ESRD and death.
Methods
To identify patients with biopsy proven renal amyloid-
osis, we conducted a retrospective search of our kidney
biopsy repository in the Department of Pathology at Yale
University using computerized medical record databases
(Copath and EPIC). The Yale University IRB committee
approved all patient biopsy material and chart reviews.
The biopsies of patients with renal amyloidosis were
reviewed by two renal pathologists (GM and MP) and
scored for the extent of amyloid deposits in the glom-
erular, vascular, or interstitial compartments. Review of
renal biopsy material included light microscopic evalu-
ation of slides stained with hematoxylin and eosin
(H&E), periodic acid Schiff (PAS), Jones silver, Klatskin
trichrome, and hematoxylin phloxine saffron (HPS)
stains. Congo red stain for amyloid was assessed by light
microscopy (LM) for the presence of salmon-colored de-
posits, which under polarized light showed apple-greenbirefringence. By electron microscopy (EM), the pres-
ence of randomly arrayed non-branching fibrils measur-
ing 8-12 nm in thickness was confirmed. The subtype of
amyloid was determined by immunofluorescence or im-
munohistochemical stains for the expression of Amyloid
A, kappa or lambda light chains.
Each patient’s biopsy was evaluated for glomerular,
vascular, and interstitial amyloid deposition by assessing
the presence and extent of Congo red positive, amorph-
ous, eosinophilic material in blood vessels, glomeruli or
interstitial space. To further grade the glomerular amyl-
oid involvement, we developed a scoring system modi-
fied from the one published by Sen and Sarcik [12]. We
assigned classes of glomerular involvement ranging from
0 to 6. Class 0 biopsies had no glomerular amyloid de-
posits. Class 1 biopsy cases showed minimal mesangial
amyloid deposition (<10% of tuft involved). Class 2 bi-
opsy cases showed mild mesangial amyloid deposition
(10-25% of tuft involved). Class 3 biopsy cases showed
segmental mesangiocapillary pattern amyloid deposition
(26-50% of tuft involved in the mesangial and capillary
compartments). Class 4 showed diffuse mesangiocapil-
lary pattern amyloid deposition (51-75% of tuft involved
in the mesangial and capillary compartments). Class 5
lesions showed membranous-pattern amyloid deposits in
glomeruli (amyloid deposits in the subepithelial com-
partment). Class 6 lesions showed advanced glomerular
amyloid deposition (>76% of tuft involved by amyloid
deposits) (Table 1).
While the scoring system described above is based
only on glomerular localization and extend of tuft in-
volvement, we developed an additional scoring system to
quantify the amount of amyloid deposition in vascular
and interstitial compartments of the renal cortex. We
applied a point grid system for the vascular and intersti-
tial areas with amyloid deposits and total points were
assigned on a scale from 0 to 3 (0 = absent, 1 =mild (1-
25%), 2 =moderate (25-75%), and 3 = severe (75-100%)),
where the percentage reflected the area of a vessel or
interstitial space filled with amyloid deposits. The final
grade for renal amyloidosis in each biopsy was assigned
by adding the scores from the two scoring systems de-
scribed above as follows: grade 1 (summary scores 1-8),
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scores 17-24) (Table 2). Moreover, scores from 0-3 were
also assigned in a similar fashion for the degree of inter-
stitial fibrosis, glomerulosclerosis and interstitial inflam-
matory infiltrate.Table 2 Patient Scoring and Grading; Gam = glomerular
amyloidosis, GS = glomerulosclerosis, Iam = interstitial
amyloidosis, IF = interstitial fibrosis, ILI = interstitial
lymphocytic infiltrate, Vam = vascular amyloidosis,
Unk = unknown
Patient Type Class Gam Vam Iam IF ILI GS Summary score
1. AL 4 3 0 1 1 0 0 2(10)
2. AA 2 1 0 2 1 1 0 1(10)
3. AA 4 3 3 1 3 2 3 3(19)
4. AL 6 3 3 1 1 2 2 3(18)
5. AA 4 3 0 2 1 1 0 2(11)
6. AL 2 1 0 0 2 1 1 1(17)
7. AL 2 1 1 0 2 2 0 1(8)
8. AA 4 3 3 2 2 1 2 3(17)
9. AL 4 3 0 2 2 1 0 2(12)
10. AA 2 1 0 0 1 1 0 1(5)
11. AL 4 2 2 2 3 1 2 2(16)
12. AL 3 1 1 2 1 1 0 2(9)
13. AL 6 3 3 2 2 2 3 3(2)
14. AA 3 2 3 1 1 0 0 2(10)
15. AL 4 3 2 0 2 2 1 2(14)
16. AL 6 3 3 1 2 2 2 3(19)
17. AL 6 3 1 2 1 0 1 2(14)
18. AL 2 3 0 0 1 1 1 1(8)
19. AL 4 3 1 1 1 1 1 2(12)
20. AL 4 3 2 1 1 1 0 2(12)
21 AL 2 3 2 0 1 1 0 2(9)
22. AL 6 3 1 2 2 1 0 2(15)
23. AL 0 0 0 1 1 2 0 1(14)
24. AL 2 3 3 0 1 0 0 2(19)
25. AL 2 1 0 0 1 1 0 1(15)
26. AA 4 3 1 1 2 0 0 2(11)
27. AL 4 3 3 1 2 1 0 2(14)
28. AA 1 1 3 2 2 2 1 2(12)
29. AL 1 1 3 1 1 1 0 1(18)
30. AA 2 3 1 0 2 2 1 2(11)
31. AL 3 2 1 1 2 2 0 2(11)
32. AA 6 3 2 2 2 2 1 3(18)
33. AA 2 1 1 1 1 1 1(18)
34. AL 1 1 3 1 2 1 2 2(11)
35. AA 4 3 3 0 2 1 1 2(14)Furthermore, the EPIC clinical data base was searched
for clinical data such as sex, age at diagnosis, clinical pres-
entation, serum creatinine levels at time of biopsy and at
time of study, serum albumin levels at time of biopsy and
at time of study, level of proteinuria, time interval from
diagnosis to ESRD or death, kidney transplant status, doc-
umented evidence of systemic amyloidosis, known amyl-
oid sub-type analysis in kidney tissue, patient’s treatment
regimen, and years of follow-up. Proteinuria, serum albu-
min and serum creatinine levels were compared and cor-
related with degree of amyloidosis.
Statistical Analysis
All statistical calculations were performed using either
the Prism 6 statistical and graphic program or Microsoft
Excel version 7 (Microsoft Corporation, NY, USA). Data
in the present study was categorical, thus comparison
between the different study groups was done using Stu-
dent t-test. All results were reported as a mean ± stand-
ard diviation. A probability value (p value) less than 0.05
was considered statistically significant, using analysis of
variance and Bonferroni t-tests.
Results
Our database search resulted in 35 patients with the bi-
opsy diagnosis of renal amyloidosis. Of these, 18 were fe-
males and 17 were males. The mean age at diagnosis
was 63 years with a range from 37 to 83 years. Review of
the biopsy tissue sections of all patients revealed the
presence of amyloid, defined by light microscopy as
homogeneous eosinophilic material in at least one of the
pertinent histological compartments of the kidney, i.e.
either media of the arteries or arterioles, mesangium or
capillary loops of glomeruli, or the renal interstitium
(Figure 1). AL type amyloid was present in 23 patients
(66%) and AA type amyloid was seen in 12 patients
(34%, Figure 2). Patients with AL amyloidosis were sig-
nificantly older (mean age 67 years) than those with the
AA type (mean age 55 years; p = 0.0015). No sex predi-
lection was found for the type of amyloid (Table 2).
The glomerular tuft was the most common site of
amyloid deposition, followed by vascular amyloid. In the
kidney biopsy tissues of almost all patients (34 of 35,
(97%)), amyloid deposits were found in the glomerular tuft,
with either mild or moderate involvement of the vessels
and/or the interstitium. However, 11% of patients showed
severe glomerular amyloidosis without vascular amyloid-
osis. Another 20% of biopsies showed mild glomerular
amyloidosis and mild to moderate vascular amyloidosis.
Only 11% of patients’ biopsies showed mild glomerular
amyloidosis but no vascular amyloid deposits (Table 3).
We further assessed the degree of interstitial fibrosis
and tubular atrophy, global glomerular sclerosis, and ex-
tend of interstitial lymphocytic infiltrate in the kidney
Figure 1 Amyloid deposits in the three major compartments of the kidney: A: Glomerular amyloid deposits predominantly in mesangial spaces
(400x, red arrow). B: Interstitial amyloidosis (200x). C: Vascular amyloidosis (100x). D: Congo Red stain of vascular amyloid deposits (100x). A-C are
H&E stained sections.
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glomerular sclerosis scores were correlated with the class
and severity of glomerular, vascular, and interstitial amyl-
oid deposition. In patients with vascular amyloidosis the
severity of amyloid deposition positively correlated with
the degree of glomerular sclerosis (Figure 3C, p = 0.016).
Patients with severe vascular amyloidosis also showedFigure 2 Analysis of AL and AA amyloid with confirmation of ultrastructura
kappa (B) light chains in glomerular amyloid deposits (400x). C: Immunohis
(400x). D: Electron microscopic image of amyloid deposits showing random
8 and 10 nm (20,000x).higher levels of serum creatinine concentration and inter-
stitial inflammatory infiltrate (Figure 3A and D).
Patients whose kidney biopsies showed severe glom-
erular amyloidosis also showed the highest levels of
serum creatinine concentrations, urine protein concen-
trations and glomerulosclerosis (Figure 4A, C, D). Pa-
tients with severe interstitial amyloidosis were comparedl characteristics: Immunohistochemistry stains for lambda (A) and
tochemistry stain for AA amyloid in glomerular amyloid deposits
ly arranged, non-branching fibrils with thickness ranging between








Severe Glomerular + severe
vascular + mild/mod interstitial
29% 16
Severe Glomerular + mild/mod
vascular + mild interstitial
29 % 15
Severe Glomerular + no
vascular + mild interstitial
11% 11
Mild Glomerular + mild/mod
vascular + mild interstitial
20% 9
Mild Glomerular + no vascular +
no interstitial
11% 6
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serum creatinine, serum albumin and urine protein con-
centrations respectively. The severity of interstitial amyl-
oidosis in kidney biopsies was inversely correlated to the
patients’ respective serum albumin levels (p = 0.012).
In order to evaluate the morbidity and mortality asso-
ciated with the degree of amyloidosis in glomerular, vas-
cular or interstitial compartments, we correlated clinical
follow-up data of our patient cohort, such as progression
to ESRD, renal replacement therapy (transplantation), or
death of the patient with their respective amyloid kidneyFigure 3 Comparison of serum and tissue parameters in mild, moderate o
increased in severe Vam cases compared to mild Vam cases (* = p < 0.05). B
in severe Vam cases, compared to mild cases. C: the grade of glomeruloscl
D: the degree of interstitial inflammatory infiltrate increased from mild to mbiopsy classification. Of the 11 patients who progressed
to ESRD all showed amyloid deposits in the glomerular
tuft. Only one patient received a kidney transplant and
subsequently also developed amyloidosis in the allo-
graft. 14 out of 35 patients (40%) had died by the time
of study review and all but one showed severe glomeru-
lar amyloidosis (93%). Only one of the patients that
had died showed mild glomerular and vascular amyl-
oidosis. Of the six patients with mild to moderate
glomerular amyloidosis, three progressed to ESRD and
one died. Conversely, those patients who had shown
minimal glomerular involvement by amyloidosis on bi-
opsy, did not progress to ESRD. When the time span
until onset of ESRD or death was compared between
patients with predominantly glomerular amyloidosis to
those with predominantly interstitial or vascular amyl-
oidosis, no statistical significance could be observed
between these patients.
Discussion
Amyloidosis is a systemic condition that is associated
with significant morbidity and mortality and renal in-
volvement with subsequent loss of renal function is one
of the factors that determines shortening of life span
[10]. In this study we have attempted to assess whether
the localization and amount of amyloid in a specificr severe vascular amyloidosis (Vam). A: Serum creatinine levels were
: The interstitial fibrosis/tubular atrophy (IFTA) grade was increased
erosis was increased in severe Vam cases, compared to mild cases.
oderate to severe vascular amyloidosis grade.
Figure 4 Comparison of serum, urine and tissue parameters in mild, moderate or severe glomerular amyloidosis (Gam). A: Serum creatinine levels
were significantly increased in severe Gam cases compared to mild Gam cases. B: The urine protein levels were significantly higher in severe Gam
cases, compared to mild Gam cases. C: The grade of glomerulosclerosis was increased in severe Gam cases, compared to mild cases. D: The
degree of interstitial inflammatory infiltrate increased from mild to moderate to severe Gam cases. * = p < 0.05.
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paired patient outcome. The identification of a certain
amyloid deposition pattern indicative of shortened pa-
tient survival would be very useful for clinical manage-
ment at time of biopsy [12]. This study shows that
severe glomerular amyloid deposition is indicative of
poor patient survival. Moreover, consistent with the lit-
erature, our patient cohort showed a higher prevalence
for AL amyloidosis than for AA amyloidosis [13]. We
found further that the mean age of our patients with AL
amyloidosis was 67 years, reflecting the age prevalence
for multiple myeloma and plasma cell dyscrasia in the
general population [13]. Our study cohort included a
high percentage of AA amyloid cases, which most likely
reflected the high incidence of chronic inflammation
and infection in our patient population.
Almost all biopsies showed amyloid deposits in the
glomerular tuft, indicating that the glomerulus is the pre-
dominant site of amyloid deposition in the kidney. Eighty
percent of biopsies with glomerular amyloid also showed
amyloid deposits in small vessels, such as arterioles or
interlobular arteries (7/34 do not have vascular→80% do).
These findings indicate that renal amyloidosis is a disease
of small vessels and glomerular capillaries, which could
explain why such a high percentage of patients with severe
amyloidosis had either died or had ESRD at the time ofour study. Patients with severe vascular amyloidosis also
showed the highest levels of inflammatory infiltrate,
which indicates that the amyloid deposits throughout
the vascular wall might initiate an interstitial inflamma-
tion due to closer proximity of vascular deposits to the
interstitial capillaries.
Patients with severe glomerular amyloidosis showed
the highest levels of serum creatinine concentrations,
proteinuria levels, and degree of glomerulosclerosis. These
findings indicate that deposition of amyloid in the glom-
erular tuft significantly reduces glomerular filtration rate,
impairs maintenance of the glomerular filtration barrier
and leads to subsequent protein loss, which may enhance
progression of renal fibrosis. Therefore we conclude that
glomerular amyloid deposits are the most important factor
influencing the overall loss of renal function in patients
with renal amyloidosis.
An important finding of our study is the observation
that 93% of the patients of our study cohort who had
died, had severe glomerular amyloidosis on kidney bi-
opsy. To the contrary, patients with mild glomerular
amyloidosis did not progress towards ESRD. Moreover,
only 50% of patients who had moderate glomerular
amyloidosis had died. These findings indicate that the
extent and amount of amyloid deposition in the glom-
erular tuft is a predictor of patient mortality. A possible
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oid deposition leads to significant proteinuria, which
may further accelerate progression of CKD.
Conclusion
Our study shows that renal involvement with amyloid-
osis has a predilection for the glomerular compartment
and that the extent and amount of amyloid deposits in
the glomerular tuft may predict patient outcome.
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